Medical Oncology最新文献_第3页

Fatty acid synthase inhibitor cerulenin attenuates glioblastoma progression by reducing EMT and stemness phenotypes, inducing oxidative and ER stress response, and targeting PI3K/AKT/NF-κB axis. 脂肪酸合成酶抑制剂cerulenin通过降低EMT和干性表型，诱导氧化和内质网应激反应，以及靶向PI3K/AKT/NF-κB轴，减缓胶质母细胞瘤的进展。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-25 DOI: 10.1007/s12032-025-02697-2

Murat Pekmez, Şefika Beyza Mete, Yunus Aksüt, İrem Öğütcü, Fatma Nur Baştürk, Yusuf Can Gerçek, Aslıhan Şengelen

{"title":"Fatty acid synthase inhibitor cerulenin attenuates glioblastoma progression by reducing EMT and stemness phenotypes, inducing oxidative and ER stress response, and targeting PI3K/AKT/NF-κB axis.","authors":"Murat Pekmez, Şefika Beyza Mete, Yunus Aksüt, İrem Öğütcü, Fatma Nur Baştürk, Yusuf Can Gerçek, Aslıhan Şengelen","doi":"10.1007/s12032-025-02697-2","DOIUrl":"10.1007/s12032-025-02697-2","url":null,"abstract":"Targeting cellular metabolism is becoming a critical approach for stopping cancer progression. Limited information is available regarding the effects of inhibiting the lipogenic enzyme fatty acid synthase (FASN) in glioblastoma (GB) cells (grade-IV-astrocytoma), which have high invasion and low response to standard treatments. Herein, we used cerulenin (CER) to inhibit FASN. CER treatments (3.6 μg/mL/48 h and 5.55 μg/mL/48 h indicate IC20 and IC50 values, respectively) led to a dose- and time-dependent decrease in the viability of the U-87MG human GB cells. A significant decrease was detected in the levels of fatty acids, including palmitic acid, determined by GS-MS analysis. FASN inhibition attenuated cell motility, 2D and 3D-clonogenic survival, and cell differentiation characteristics (related markers of epithelial-mesenchymal transition/EMT and stemness). Moreover, treatments caused mitochondrial membrane potential (MMP) collapse and increased intracellular reactive oxygen species (ROS) levels. Protein aggregates and ER stress in the cells also increased. Remarkably, despite increased Hsp70 and p-HSF1 levels against induced cellular stress, CER promoted markedly autophagy and apoptosis. The network pharmacology approach revealed that protein and lipid kinases are crucial targets in cell signaling, and PI3K, AKT, and NF-κB levels were confirmed by immunoblotting. The results demonstrated for the first time that inhibiting FA production and FASN function induces cell death through ROS generation and ER stress while simultaneously reducing the motility and aggressiveness of U-87MG human glioblastoma cells by attenuating EMT and stemness phenotypes. Therefore, blocking lipid metabolism using CER may be considered as a good candidate for GB therapeutic option.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 5","pages":"136"},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smart nanomedicines powered by artificial intelligence: a breakthrough in lung cancer diagnosis and treatment. 人工智能驱动的智能纳米药物：肺癌诊断和治疗的突破。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-25 DOI: 10.1007/s12032-025-02680-x

Moloudosadat Alavinejad, Maryam Shirzad, Mohammad Javad Javid-Naderi, Abbas Rahdar, Sonia Fathi-Karkan, Sadanand Pandey

{"title":"Smart nanomedicines powered by artificial intelligence: a breakthrough in lung cancer diagnosis and treatment.","authors":"Moloudosadat Alavinejad, Maryam Shirzad, Mohammad Javad Javid-Naderi, Abbas Rahdar, Sonia Fathi-Karkan, Sadanand Pandey","doi":"10.1007/s12032-025-02680-x","DOIUrl":"https://doi.org/10.1007/s12032-025-02680-x","url":null,"abstract":"Lung cancer remains one of the leading causes of cancer-related mortality worldwide, primarily due to challenges in early detection, suboptimal therapeutic efficacy, and severe adverse effects associated with conventional treatments. The convergence of nanotechnology and artificial intelligence (AI) offers transformative potential in precision oncology, enabling innovative solutions for lung cancer diagnosis and therapy. Intelligent nanomedicines facilitate targeted drug delivery, enhanced imaging, and theranostic applications, while AI-driven models harness big biomedical data to optimize nanomedicine design, functionality, and clinical application. This review explores the synergistic integration of AI and nanotechnology in lung cancer care, highlighting recent advancements, key challenges, and future directions for clinical translation. Ethical considerations, including data standardization and privacy concerns, are also addressed, providing a comprehensive roadmap to overcome current barriers and advance the adoption of AI-driven intelligent nanomedicines in precision oncology. This synthesis underscores the critical role of emerging technologies in revolutionizing lung cancer management.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 5","pages":"134"},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction Note: Molecular and therapeutic effect of CRISPR in treating cancer. 注：CRISPR在治疗癌症中的分子和治疗作用。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-24 DOI: 10.1007/s12032-025-02692-7

Sawani Rodrigo, Kaveesha Senasinghe, Sameer Quazi

引用次数: 0

Molecular crosstalk between GPCR and receptor tyrosine-protein kinase in neuroblastoma: molecular mechanism and therapeutic implications. 神经母细胞瘤中GPCR与酪氨酸蛋白激酶受体之间的分子串扰：分子机制及其治疗意义。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-23 DOI: 10.1007/s12032-025-02685-6

Kousik Maparu, Dhrita Chatterjee, Romanpreet Kaur, Nileshwar Kalia, Omkar Kumar Kuwar, Mayank Attri, Shamsher Singh

{"title":"Molecular crosstalk between GPCR and receptor tyrosine-protein kinase in neuroblastoma: molecular mechanism and therapeutic implications.","authors":"Kousik Maparu, Dhrita Chatterjee, Romanpreet Kaur, Nileshwar Kalia, Omkar Kumar Kuwar, Mayank Attri, Shamsher Singh","doi":"10.1007/s12032-025-02685-6","DOIUrl":"https://doi.org/10.1007/s12032-025-02685-6","url":null,"abstract":"Neuroblastoma is an aggressive pediatric tumor condition derived from neural crest cells that typically affect infants and children under the age of five. It can often originate in the adrenal glands but can also develop in the sympathetic nervous system. G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases have been shown in recent research to have a vital role in the progression of neuroblastoma. GPCR-RTK crosstalk stimulates signaling pathways such as MAP kinase, and the activation of the GPCR-AKT signaling pathway plays a critical role in neuroblastoma progression by promoting cell growth, survival, and resistance to apoptosis through complex interactions with insulin signaling pathways. ALK (Anaplastic lymphoma kinase), a member of the RTK family, and any mutations can lead to oncogenic signaling and resistance to targeted therapy in neuroblastoma. By interfering with cellular signaling via novel therapeutic strategies by selective RET inhibitors, ALK inhibitors, and Trk-specific inhibitors may be able to reduce the prevalence of neuroblastoma. Understanding the complicated signaling relationships between GPCRs, RTKs, and the insulin pathway is critical when developing new cancer treatments. The integration of these signaling networks offers promising avenues for enhancing the effectiveness of existing treatments and improving patient outcomes in neuroblastoma.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 5","pages":"131"},"PeriodicalIF":2.8,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction Note: Niosomes: a novel targeted drug delivery system for cancer. 撤稿说明：Niosomes：一种新型癌症靶向给药系统。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-22 DOI: 10.1007/s12032-025-02693-6

Maryam Moghtaderi, Kamand Sedaghatnia, Mahsa Bourbour, Mahdi Fatemizadeh, Zahra Salehi Moghaddam, Faranak Hejabi, Fatemeh Heidari, Sameer Quazi, Bahareh Farasati Far

引用次数: 0

Retraction Note: In vitro cytotoxicity and anti-cancer drug release behavior of methionine-coated magnetite nanoparticles as carriers. 撤回注：甲硫氨酸包被的磁性纳米颗粒作为载体的体外细胞毒性和抗癌药物释放行为。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-22 DOI: 10.1007/s12032-025-02688-3

Faten Eshrati Yeganeh, Amir Eshrati Yeganeh, Mahdi Fatemizadeh, Bahareh Farasati Far, Sameer Quazi, Muhammad Safdar

引用次数: 0

Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials. KRAS -G12C抑制剂治疗结直肠癌的疗效和安全性：临床试验的系统综述

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02684-7

Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, Sama Hesham Samir, Swastik Pandita, Fatima Saeed, Dina Elraggal, Hebatullah Abdulazeem, Anwaar Saeed

{"title":"Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials.","authors":"Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, Sama Hesham Samir, Swastik Pandita, Fatima Saeed, Dina Elraggal, Hebatullah Abdulazeem, Anwaar Saeed","doi":"10.1007/s12032-025-02684-7","DOIUrl":"10.1007/s12032-025-02684-7","url":null,"abstract":"Patients with colorectal cancer (CRC) who have KRAS mutations often see poor results with standard treatments, leaving them with fewer viable options. Over the past few years, new KRAS G12C inhibitors have emerged as a targeted approach for a specific subset of these mutations, though their effectiveness and safety in advanced CRC remain areas of ongoing research. In this systematic review, we identified nine clinical trials including a total of 668 patients, by searching PubMed, Web of Science, CENTRAL, and Embase through October 2024. When sotorasib was used alone, the objective response rate (ORR) ranged from 7.1 to 9.7%, with disease control (DC) rates of 73.8 to 82.3% and a median progression-free survival (PFS) spanning 4-5.6 months. Combining sotorasib with panitumumab, especially at higher doses, raised its ORR to 26.4%. Meanwhile, pairing adagrasib with cetuximab led to a 42% ORR and a median PFS of 6.9 months, surpassing the 19% ORR observed with adagrasib alone. Divarasib monotherapy produced a 36% ORR and an 85.5% DC rate, with a PFS of 5.6 months; in tandem with cetuximab, those numbers climbed to a 62.5% ORR and a PFS of 8.1 months. Common side effects across these trials included diarrhea, nausea, fatigue, and various skin reactions. Overall, KRAS G12C inhibitors appear to offer meaningful benefits for CRC patients, particularly when used alongside EGFR inhibitors like cetuximab or panitumumab. However, further large-scale, randomized trials are needed to refine dosing strategies and gain a clearer picture of both efficacy and potential risks.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"127"},"PeriodicalIF":2.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prevalence of post-therapy epilepsy in patients treated for high-grade glial tumors: a systematic review and meta-analysis. 高级别神经胶质肿瘤患者治疗后癫痫的患病率：一项系统回顾和荟萃分析。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02677-6

Marta Pereira Ferreira, Ruben Lopes Carvalho, Daniel Filipe Borges, Joana Isabel Soares, João Casalta-Lopes

{"title":"The prevalence of post-therapy epilepsy in patients treated for high-grade glial tumors: a systematic review and meta-analysis.","authors":"Marta Pereira Ferreira, Ruben Lopes Carvalho, Daniel Filipe Borges, Joana Isabel Soares, João Casalta-Lopes","doi":"10.1007/s12032-025-02677-6","DOIUrl":"10.1007/s12032-025-02677-6","url":null,"abstract":"Gliomas are the most prevalent type of primary brain tumor of the adult central nervous system. High-grade gliomas (HGG) are the most common type of glioma. Epilepsy is often the first clinical manifestation of HGG. Since epilepsy leads to increased morbidity and mortality rates, seizure control is one of the main therapeutic goals for patients with glioma-related epilepsy. Post-therapy epilepsy is observed in a significant percentage of patients, hence, this work aimed to quantify the prevalence of post-therapy epilepsy after HGG treatment. Our search was conducted across PubMed®, EMBASE®, Web of Science™, Cochrane Library, Sicelo and Scopus, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. This review included articles published in Portuguese or English that evaluate adult patients with newly diagnosed HGG, who were treated with at least surgery or radiation. Thirty-six studies reporting on 4036 HGG patients were included in our meta-analysis. The mean age ranged from 44 to 73 years. Glioblastoma was the most commonly observed HGG, representing 77,8% of all glioma patients. The pre-treatment seizure frequency was observed in 21,2%. All patients underwent surgery as the main therapy, and 1842 patients received standard adjuvant therapy. We also observed a pooled prevalence of post-therapy seizures of 25.5% (95% confidence interval of [19.9%; 31.1%]). Substantial heterogeneity in all assessed variables was observed. Conducting larger prospective studies with suitable epilepsy diagnostic methods would help provide a more precise estimate of the number of HGG patients who develop post-therapy epilepsy.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 4","pages":"128"},"PeriodicalIF":2.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Urinary extracellular vesicle‑derived miR‑126‑3p predicts lymph node invasion in patients with high‑risk prostate cancer. 更正：尿细胞外囊泡来源的miR - 126 - 3p预测高危前列腺癌患者的淋巴结浸润。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02636-1

Liang Dong, Cong Hu, Zehua Ma, Yiyao Huang, Greg Shelley, Morgan D Kuczler, Chi-Ju Kim, Kenneth W Witwer, Evan T Keller, Sarah R Amend, Wei Xue, Kenneth J Pienta

引用次数: 0

Correction to: The role of histamine and its receptors in breast cancer: from pathology to therapeutic targets. 更正：组胺及其受体在乳腺癌中的作用：从病理学到治疗目标。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-03-21 DOI: 10.1007/s12032-025-02672-x

Hossein Azimi, Afifeh Jafari, Mahafarin Maralani, Homa Davoodi

引用次数: 0